Abstract:
Compounds useful as fluorescent or colored dyes are disclosed. The compounds have the following structure (I):
or a stercoisomer, tantomer or salt thereof, wherein R1, R2, R3, R4, R5, L1, L2, L3, L4, M, m and n are as defined herein. Methods associated with preparation and use of such compounds are also provided.
Abstract:
This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases or disorders related to misregulation of the Complement cascade pathway. More particularly, this disclosure relates to macrocyclic compounds and pharmaceutical compositions thereof, methods of inhibiting Complement Factor B (CFB) expression with these compounds, and methods of treating diseases or disorders mediated by CFB.
Abstract:
The present invention relates to an. organic semiconductive layer which is an electron transport layer and/or an electron injection layer and/or an n-type charge generation layer, the organic semiconductive layer comprising at least one compound of formula (1) wherein R1 and R2 are each independently selected from C1 to C16 alkyl; Ar1 is selected from C6 to C14 arylene or C3 to C12 heteroarylene; Ar2 is independently selected from C14 to C40 arylene or C8 to C40 heteroarylene; R3 is independently selected from H, C1 to C12 alkyl or C10 to C20 aryl; wherein each of Ar1, Ar2 and R3 may each independently be unsubstituted or substituted with at least one C1 to C12 alky group; n is 0 or 1; and m is 1 in case of n=0; and m is 1 or 2 in case of n=1, phosphine oxide compounds comprised therein and to organic electroluminescent devices comprising such layers and compounds.
Abstract:
Compounds useful as fluorescent or colored dyes are disclosed. The compounds have the following structure (I): or a stereoisomer, tautomer or salt thereof, wherein R1, R2, R3, R4, R5, L1, L2, L3, L4, M, m and n are as defined herein. Methods associated with preparation and use of such compounds are also provided.
Abstract:
Compounds useful as fluorescent or colored dyes are disclosed. The compounds have the following structure (I): including stereoisomers, salts and tautomers thereof, wherein R1, R2, R3, L1, L2, L3, L4, L5, L6, M1, M2, A, q, w and n are as defined herein. Methods associated with preparation and use of such compounds are also provided.
Abstract:
A condensed cyclic compound and an organic light-emitting device including the condensed cyclic compound, the condensed cyclic compound being represented by one of Formulae 1-1 to 1-8 described herein.
Abstract:
Compounds useful as fluorescent or colored dyes are disclosed. The compounds have the following structure (I): or a stereoisomer, tautomer or salt thereof, wherein R1, R2, R3, R4, R5, L1, L2, L3, L4, M, m and n are as defined herein. Methods associated with preparation and use of such compounds are also provided.
Abstract:
The present disclosure is directed to compounds of the structure (X): wherein: n is 2 or 3; NHE has the structure wherein: R1 is H or —SO2—NR7R8—; R2 is selected from H, —NR7(CO)R8, —SO2—NR7R8— and —NR7R8; R3 is hydrogen; R7 is hydrogen; R8 is a bond linking to L; L is a polyalkylene glycol linker; and Core has the following structure: wherein: X is selected from the group consisting of a bond, —O—, —NH—, NHC(═O)—, —NHC(═O)NH— and —NHSO2—; and Y is selected from the group consisting of a bond, optionally substituted C1-6 alkylene, optionally substituted benzene, pyridinyl, a polyethylene glycol linker and —(CH2)1-6O(CH2)1-6—, and methods of using such compounds for the treatment of irritable bowel syndrome, chronic kidney disease and end-stage renal disease.